Paxil Tapering Guide
paroxetine
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.
Overview
Paroxetine is an SSRI with notable anticholinergic activity, approved for major depressive disorder, OCD, panic disorder, social anxiety disorder, GAD, and PTSD. It is widely recognized as one of the more difficult SSRIs to discontinue.
10mg, 20mg, 30mg, 40mg
Tablets: 10mg, 20mg, 30mg, 40mg; Oral suspension: 10mg/5mL; Controlled-release (CR) tablets: 12.5mg, 25mg, 37.5mg
Category D (positive evidence of risk — cardiac malformations)
Mechanism of Action
Potent and selective inhibitor of serotonin reuptake (SERT). Also has significant anticholinergic (muscarinic) activity and weak norepinephrine reuptake inhibition, which contribute to its withdrawal profile.
Taper Notes
Short half-life and non-linear kinetics make paroxetine one of the harder SSRIs to discontinue. Hyperbolic reductions essential; oral suspension (10 mg/5 mL) preferred for precise sub-tablet dosing.
Maudsley Deprescribing Guidance
Discontinuation is complicated by short half-life and anticholinergic rebound. A markedly slow terminal taper (months, not weeks) is essential. Consider fluoxetine cross-taper for refractory cases.
Tapering Protocol
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Initial reductions | 4-6 weeks | Reduce by ~10–25% per step using available tablet strengths. Anticholinergic rebound (sweating, GI cramping, vivid dreams) may emerge in this phase. |
| Middle reductions | 6-8 weeks | Transition to oral suspension or CR tablets for smoother plasma curves. CR-to-IR conversion is not 1:1 (12.5 mg CR ≈ 10 mg IR). |
| Lower dose reductions | 6-8 weeks | CYP2D6 auto-inhibition produces non-linear kinetics — small absolute reductions have disproportionately large pharmacodynamic effects. Use 10% proportional cuts. |
| Final reductions | 8-16 weeks | Liquid suspension is typically required for sub-mg increments. Hold periods of 4+ weeks per step are often necessary at this stage. |
Withdrawal Timeline
12-24 hours after missed dose (shortest onset of all SSRIs)
2-5 days
2-6 weeks for most symptoms
Electric shock sensations, emotional lability, and derealization can persist 2-6 months. Paxil has the highest rate of protracted withdrawal among SSRIs.
Clinical Pearls
Practical considerations for clinicians supervising Paxil tapers.
- 1Oral suspension (10 mg/5 mL) is the preferred dosing tool below 10 mg; paroxetine tablets fragment unevenly and yield inconsistent doses.
- 2CYP2D6 auto-inhibition makes paroxetine pharmacokinetics non-linear at clinical doses; expect proportional reductions to feel larger than the absolute mg change.
- 3Anticholinergic rebound (diaphoresis, GI cramping, vivid dreaming) is distinctive among SSRIs and reflects muscarinic receptor unmasking. Reassure the patient — symptoms are time-limited.
- 4When converting between CR and IR formulations, do not assume 1:1 equivalence; 12.5 mg CR approximates 10 mg IR. Verify dose-equivalence before formulation switches.
- 5For refractory discontinuation, fluoxetine cross-taper is an option (per Maudsley): substitute 20 mg fluoxetine for the patient's paroxetine dose, allow 2–4 weeks, then taper fluoxetine. Weigh complexity against patient burden.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- MAOIs — contraindicated (serotonin syndrome risk)
- Thioridazine — contraindicated (QT prolongation via CYP2D6 inhibition)
- Pimozide — contraindicated
Food Interactions
- No significant food effect on absorption
- Avoid alcohol during treatment
Contraindications
- MAOIs within 14 days
- Thioridazine
- Pimozide
Toxicity
Serotonin syndrome risk. Anticholinergic toxicity at high doses. Associated with higher rates of discontinuation syndrome than other SSRIs.
Pharmacokinetics
ADME Profile
Completely absorbed after oral dosing but extensive first-pass metabolism reduces bioavailability to ~50%. Tmax ~5 hours. Food does not significantly affect absorption.
~8.7 L/kg
Extensively metabolized hepatically via CYP2D6 (primary) with CYP3A4 contribution. Paroxetine inhibits its own metabolism (CYP2D6 saturation), leading to non-linear pharmacokinetics.
Renal (~64% as metabolites, ~2% unchanged) and fecal (~36%).
~93–95%
Non-linear; clearance decreases at higher doses due to CYP2D6 saturation.
Build Paxil taper plans in minutes
TaperMeds turns these protocols into prescriber-ready taper schedules with hyperbolic dose curves, symptom tracking, and patient handouts — for the clinicians supervising the taper.
Try TaperMeds